Clinical Trials
2.9k
Active:461
Completed:1179
Trial Phases
6 Phases
Early Phase 1:76
Phase 1:723
Phase 2:1006
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2395 trials with phase data)• Click on a phase to view related trials
Phase 2
1006 (42.0%)Phase 1
723 (30.2%)Not Applicable
459 (19.2%)Phase 3
102 (4.3%)Early Phase 1
76 (3.2%)Phase 4
29 (1.2%)Opiophobia in Adults With Advanced Cancer
Not yet recruiting
- Conditions
- Cancer
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT07093567
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomized Controlled Trial (EHR Study #3)
Not yet recruiting
- Conditions
- Communication SkillsProfessionalismRandomized Controlled TrialPerception
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 88
- Registration Number
- NCT07089953
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
Not Applicable
Not yet recruiting
- Conditions
- Uterine Leiomyosarcoma
- Interventions
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT07076186
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 768
- Registration Number
- NCT07076485
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT07076498
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 578
- Next
News
No news found